Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.